0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bionik Laboratories
Its shares trade under the ticker BNKL. It has been listed since 12 June 2012. In the fiscal year to 31 March 2023, it reported revenue of $1.8m and a net loss of $4.9m. At that date it held total assets of $3.4m and shareholders' equity of −$1.6m.
Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2012-06-12. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and deliver recovery for patients with neurological or mobility impairments. The company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and three products in varying stages of development. Its InMotion ARM, and InMotion ARM/HAND products are robotic therapies for the upper limbs. In addition to these fully developed, clinical rehabilitation solutions, it is also developing InMotion Home, which is an upper extremity product that allows the patient to extend their therapy for as long as needed while rehabilitating at home. Its other products are InMotion Robots and InMotion CONNECT.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Jun 2012
- Employees
- 12
- Website
- bioniklabs.com ↗
Leadership
Pay as last reported
- Mr. Richard RussoPresident, Chief Executive Officer, Director, since 2020$361,398
- Mr. Daniel GonsalvesChief Financial Officer, Executive Vice President$255,129
- Mr. Remi Gaston-DreyfusIndependent Director$50,000
- Mr. Michal PrywataIndependent Director, since 2011$50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bionik Laboratories Corp. has three products on the market including InMotion ARM and InMotion ARM/HAND for upper limb rehabilitation.
- The company employs 12 full-time staff focused on AI-driven rehabilitation solutions for neurological disorders.
- InMotion Home is in development as a home-based upper extremity rehabilitation product extending therapy duration.
Weaknesses
- The company has only 12 employees, which may limit operational capacity and scalability.
- Bionik Laboratories Corp. has three products in development stages, indicating potential delays in market entry.
- The company's IPO in 2012 may not provide sufficient capital for rapid expansion.
Opportunities
- The growing demand for AI-driven rehabilitation solutions in the Health Care sector presents a market opportunity.
- Expanding the InMotion Home product line could capture a larger share of home-based therapy users.
- Developing new products for lower extremity rehabilitation could address unmet needs in mobility impairment.
Threats
- Competition from established players in the Health Care industry could challenge market share.
- Regulatory changes in the Health Care sector might increase compliance costs and complexity.
- Economic downturns could reduce healthcare spending on rehabilitation technologies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.